Aug 29, 2023 1:30pm EDT JanOne Earns US Patent for the Use of its Novel Formulation of Low-Dose Naltrexone, Jan123, to Treat Chronic Pain
Aug 25, 2023 2:30pm EDT JanOne Wins "Best Abstract" Award at the Ohio Society of Interventional Pain Physicians Annual Meeting
Aug 22, 2023 5:30pm EDT JanOne Technologies Announces Closing of Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Aug 18, 2023 7:00pm EDT JanOne Technologies Announces Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Aug 18, 2023 12:42pm EDT JanOne to Present Prior Phase II Data on Diabetic Neuropathy at the Ohio Society of Interventional Pain Physicians Annual Meeting
Jun 28, 2023 8:30am EDT JanOne files international patent application for methods of using low dose naltrexone to treat chronic pain
Apr 13, 2023 8:30am EDT JanOne to Present Data On Its Two Non-Opioid Drug Candidates at The Appalachian Region Spine and Pain Meeting on Drug Development Programs to Treat Pain on April 15, 2023
Mar 24, 2023 11:02am EDT JanOne Technologies Announces Closing of Registered Direct Offering of Common Stock Priced At-The-Market
Mar 23, 2023 8:30am EDT JanOne Welcomes John Bonfiglio -- Veteran Biotech Executive, Deal Maker and Strategist -- to Top Management Team
